Cargando…

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity

PURPOSE: The purpose of this study was to report on the axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for threshold retinopathy of prematurity. METHODS: The authors conducted a comparative, consecutive, original study. RESULTS: Twenty-five ey...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chun-Ju, Tsai, Yi-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959583/ https://www.ncbi.nlm.nih.gov/pubmed/27499611 http://dx.doi.org/10.2147/OPTH.S110717

Ejemplares similares

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
por: Chen, Yen-Chih, et al.
Publicado: (2018)

Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity
por: Pawar, Neelam, et al.
Publicado: (2023)

Retinal, visual, and refractive development in retinopathy of prematurity
por: Moskowitz, Anne, et al.
Publicado: (2016)

Retinal Vascular Oxygen Saturation and Its Variation With Refractive Error and Axial Length
por: Lim, Laurence Shen, et al.
Publicado: (2019)

Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022)

Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
por: Wu, Lei, et al.
Publicado: (2023)

The Development of Retinal Function and Refractive Error in Children With Retinopathy of Prematurity
por: De Bruyn, Hanna, et al.
Publicado: (2023)

Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity
por: Simmons, Michael, et al.
Publicado: (2021)

Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016)

Modeling absolute zone size in retinopathy of prematurity in relation to axial length
por: Wang, Sean K., et al.
Publicado: (2022)

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
por: Jin, Enzhong, et al.
Publicado: (2019)

Effect of ranibizumab on retinopathy of prematurity: A meta-analysis
por: Wang, Zhibin, et al.
Publicado: (2022)

Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment
por: Lien, Reyin, et al.
Publicado: (2016)

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019)

Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography
por: Al Rasheed, Raghad, et al.
Publicado: (2022)

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
por: Chan, Joyce J. T., et al.
Publicado: (2016)

Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment
por: Gotz-Więckowska, Anna, et al.
Publicado: (2017)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
por: Chen, Jing, et al.
Publicado: (2023)

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
por: Patel, Samir N, et al.
Publicado: (2019)

Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity
por: Chandra, Parijat, et al.
Publicado: (2019)

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
por: Prajapati, Vipul, et al.
Publicado: (2023)

Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
por: Alva, Niza, et al.
Publicado: (2023)

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
por: Huang, Qiujing, et al.
Publicado: (2017)

Intravitreal ranibizumab as salvage therapy in an extremely low–birth-weight infant with rush type retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2012)

Refractive status and optical components of premature babies with or without retinopathy of prematurity at 7 years old
por: Wang, Yang, et al.
Publicado: (2020)

Bevacizumab or laser for aggressive posterior retinopathy of prematurity
por: Blair, Michael, et al.
Publicado: (2018)

Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity
por: Mota, Ágata, et al.
Publicado: (2012)

Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query
por: Al Kalbani, Khulood, et al.
Publicado: (2023)

Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences
por: Deissler, Heidrun L, et al.
Publicado: (2012)

The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries
por: Wu, Annie M., et al.
Publicado: (2018)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

Comparison of intravitreal injection of ranibizumab versus bevacizumab for treatment of type 1 and aggressive retinopathy of prematurity in rural Egypt. A randomized clinical trial
por: Tawfik, Ghada Mahmoud, et al.
Publicado: (2022)

Speed of Retinal Vascularization in Retinopathy of Prematurity: Risk and Protective Factors
por: Solans Pérez de Larraya, Ana Maria, et al.
Publicado: (2019)

Refractive Status of Chinese with Laser-Treated Retinopathy of Prematurity
por: Ruan, Lu, et al.
Publicado: (2015)

Role of deferred retinal laser following intravitreal injection of bevacizumab in treatment of severe retinopathy of prematurity
por: Bhat, Vishalakshi, et al.
Publicado: (2023)

Lasting Controversy on Ranibizumab and Bevacizumab
por: Zou, Lihui, et al.
Publicado: (2011)

Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment
por: Chang, Yu-Shan, et al.
Publicado: (2019)

Comment on “bevacizumab or laser for aggressive posterior retinopathy of prematurity”
por: Samanta, Ramanuj
Publicado: (2019)

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain
por: Obata, Shumpei, et al.
Publicado: (2021)

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo, Odalis, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_haedq90gg3kft4h6mfg0j8ki9c